ROS1 and non-small cell lung carcinoma: Chu et al. published a similar clinical trial-to-clinical trial comparison that included entrectinib pivotal data from the ALKA-372-001, STARTRK-1, and STARTRK-2 studies in ROS1-positive NSCLC and matching-adjusted indirect comparison (MAIC) of crizotinib from PROFILE 1001 and individual patient data (IPD) for entrectinib [57].